Endo Ascvd Risk Assessment Guide Lipid Therapy Obesity

---
name: endo-ascvd-risk-assessment-guide-lipid-therapy-obesity
description: Recommends assessing 10-year atherosclerotic cardiovascular disease risk using the Pooled Cohort Equations to guide lipid-lowering therapy initiation in adults with obesity. Triggers include obese patient needing lipid-lowering therapy decision, assessing when to start statin in obesity, and using risk score to guide treatment in obesity.
---

# 10-year ASCVD risk assessment to guide lipid-lowering therapy in obesity

## STEP 1 — Gather Information
Collect data for Pooled Cohort Equations: age, sex, race, total cholesterol, HDL-C, systolic blood pressure, hypertension treatment status, diabetes status, smoking status; confirm obesity (BMI ≥30 kg/m2) and optionally waist circumference.  
**Action:** Compile variables for 10-year ASCVD risk calculation.

## STEP 2 — Rule In / Rule Out
Determine if patient has established ASCVD or long-standing diabetes. If yes, lipid-lowering therapy is indicated regardless of risk score (proceed to Decide). If no, proceed to calculate 10-year ASCVD risk.  
**Decision:** Either initiate lipid-lowering therapy or continue to risk assessment.

## STEP 3 — Classify or Stratify
Calculate 10-year ASCVD risk using Pooled Cohort Equations; categorize as low (<5%), borderline (5-7.4%), intermediate (7.5-19.9%), or high (≥20%). Assess for risk-enhancing factors: family history of premature ASCVD, elevated Lp(a) ≥50 mg/dL, metabolic syndrome, CKD, chronic inflammatory conditions, high-risk race/ethnicity.  
**Action:** Assign risk category and document presence of risk-enhancing factors.

## STEP 4 — Decide
Based on risk category and risk-enhancing factors: low risk (<5%) with no risk-enhancing factors → lifestyle therapy only; low risk with risk-enhancing factors → consider statin after clinician-patient discussion; borderline (5-7.4%) with risk-enhancing factors → recommend statin; intermediate (7.5-19.9%) or high (≥20%) → recommend statin; if uncertainty in borderline/intermediate risk, consider coronary artery calcium (CAC) scoring to reclassify.  
**Decision:** Initiate or withhold lipid-lowering therapy (statin ± ezetimibe/PCSK9i) based on final risk stratification.

## Clinical Guardrails / Mimics / Pitfalls
Do not rely solely on LDL-C thresholds without risk assessment in obesity; ensure smoking and hypertension treatment status are included in risk calculation; avoid using non-fasting triglycerides >500 mg/dL for LDL-C estimation without fasting confirmation; remember obesity itself is a risk-enhancing factor; do not use CAC=0 to avoid statin in high-risk patients with diabetes, familial hypercholesterolemia, or established ASCVD.

## Concrete Clinical Example
58-year-old man with BMI 31, ex-smoker (quit 5 years ago), untreated hypertension (SBP 148), total cholesterol 210 mg/dL, HDL 38 mg/dL, no diabetes. 10-year ASCVD risk = 14.2% (intermediate). No additional risk-enhancing factors. Decision: initiate moderate-intensity statin therapy.

**Source:** Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2020, doi:10.1210/clinem/dgaa674
> **TODO:** consider adding scripts/calc.py for the endo-ascvd-risk-assessment-guide-lipid-therapy-obesity calculator